Take a look at the beta version of dw.com. We're not done yet! Your opinion can help us make it better.
Despite its many mutations, experts are not overly concerned about IHU coronavirus variant B.1.640.2, first discovered in a traveler returning from Cameroon to France.
Not all coronavirus variants are equal — omicron may multiply more in the tissue of the nose and throat than in the lungs
The World Health Organization has said that the new coronavirus variant B.1.640.2, first detected in France, is not a variant of concern.
WHO scientist Abdi Mahmud said that the WHO has been monitoring the variant since November. "That virus has had a lot of chances to pick up," he said Tuesday in Geneva.
Only about 20 samples have been sequenced, compared to more than 120,000 of the omicron variant in the variant-tracking Gisaid database.
Separately, Tom Peacock, a virologist at Imperial College in London, tweeted earlier this week that this variant is currently "not one worth worrying about too much":
The new variant was detected in early December in a traveler who returned to France from Cameroon, a clinic at the hospital IHU Mediterrannee in Marseille reported. The returnee from Cameroon reportedly infected 12 people in southern France.
This new variant, called B.1.640.2, has 46 mutations in an "atypical combination," according to a preprint study that has not yet been peer-reviewed.
According to this study, the two already known spike protein mutations N501Y and E484K are also found in the new coronavirus variant. The N501Y mutation, for example, was detected very early in the alpha variant. It causes the pathogen to bind more strongly to human cells and thus to spread more easily in the body.
E484K is one of the escape mutations located directly in the spike protein and thus possibly reduces the effectiveness of COVID-19 vaccines.
But what these mutations mean and whether the new coronavirus variant B.1.640.2 is actually more contagious than the original SARS-CoV-2 virus cannot yet be said with any real confidence, due to the lack of available data and the small number of cases.
Jörg Timm, head of the Institute for Virology at University Hospital Düsseldorf, believes that the new variant isn't extremely dangerous.
"The variant was first described a little while ago and hasn't become more prominent in areas where a lot of sequencing is being done," he said. "It hasn't spread widely."
Timm added that this was a marked difference to the omicron variant, which researchers realized from the start would spread very quickly.
"Nobody expects that the B.1640 variant will cause truly significant problems," Timm said. "Of course you'll have to add a small question mark to that, but this is my current view of it."
We do not yet know anything about the origin of this new variant, either. The fact that B.1.640.2 has now been detected for the first time in a returnee from Cameroon does not mean that the variant has also emerged in the Central African country.
Despite this encouraging information, health authorities in Cameroon — where the variant may have originated — continue to prepare for developments.
"We are monitoring this closely and we are continuing to have local sequences so that we can compare and see if we have these variants circulating among us," Cameroonian epidemiologist Yap Boum told DW in an interview in French.
Very low vaccination rates generally favor the emergence of new coronavirus mutations. In Cameroon, only 2.4% of the population is fully vaccinated, according to data from the Johns Hopkins University in Baltimore in the United States.
As long as the vaccination campaign isn't advanced globally, new variants will continue to develop. Sometimes they are more harmless, sometimes more dangerous. It remains to be seen how harmful this new variant will be.
Omicron attacks the lungs less severely — therefore, COVID-19 patients require artificial respiration less often
Public concern around potential new variants has increased due to the lightning-speed spread of the omicron variant.
Yet epidemiologist Didier Raoult — who was behind the preprint study — is controversial, among other reasons because he treats COVID-19 patients with the malaria medication hydroxychloroquine, which has not been proven effective.
In an investigation, German public media outlet Tagesschau found that the French chamber of doctors had reprimanded Raoult for this at the start of December. Additionally, his clinic at IHU Mediterrannee in Marseille has violated the rules of clinical studies in connection to studies around COVID-19, Tagesschau reported. Raoult founded the clinic but has since stepped down as director.
The doctor has himself not been vaccinated, as he believes COVID-19 is not deadly. He enjoys a kind of cult status among COVID-19 skeptics — which may have helped contribute to spread of the preprint. Whether scientific standards were followed in this study has not yet been established.
We already know that the omicron variant is much more contagious and is spreading rapidly around the world. But at the same time, the courses are much milder in most patients, as ever more studies are confirming.
It is also gradually becoming clearer which factors are at work here. The T-cells of vaccinated and recovered persons react to omicron, thus protecting most infected persons from a severe course of COVID-19.
It is true that the mutations in omicron have altered the spike protein such that the antibodies generated by previous infection or vaccination are no longer as protective.
But the acquired immune response by T-cells still works in 70% to 80% of cases, similar to the older beta and delta variants, researchers from Cape Town, South Africa, found. The T-cells of vaccinated and recovered patients recognized omicron nearly as well as the original coronavirus variant, the group concluded.
In addition, the omicron variant attacks the lungs much less frequently, researchers from Japan and the US found in animal studies.
Instead, the omicron variant is more likely to attack the upper respiratory tract, such as the nose, throat and trachea, according to the study, which also has not yet been peer-reviewed.
The viral load in the noses of hamsters and mice infected with omicron was just as high as with earlier mutations. But in the lungs, the viral load and thus the damage was significantly less.
In mid-December, researchers at the University of Hong Kong came to very similar conclusions. They found that although the omicron variant infects the bronchus up to 70 times faster than the delta variant and multiplies there, it spreads up to 10 times less in lung tissue.
These research findings are in line with observations from the UK. There, too, the highly contagious omicron variant is causing a sharp rise in the number of infections.
But at the same time, the statistical risk of having to be treated in a hospital is reduced by a third compared to the delta variant. The number of patients requiring artificial respiration is also largely unchanged, despite the significantly higher infection rate with omicron.
That's a reason for hope; however, concerns remain. The significantly higher case numbers are a major challenge for overburdened health care systems.
And those who have not yet been vaccinated, or recovered from a previous COVID-19 infection, can still fall seriously ill if they contract the omicron variant.
This article was translated from German and first published in English on January 4.
The story was adjusted on January 5 to reflect what is known about mutations in the omicron variant. A statement by Jörg Timm was added as well. It was updated on January 7 to reflect further information about the new variant. The passage on the "Flurona" case in Israel was removed.